| Paper | Authors | Journal | Year | Type |
|---|
| Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy men and women | Jin Z et al. | Appetite | 2026 | Randomized Controlled Trial |
| Coated glucose microbeads stimulate enteric hormone release and improve glucose tolerance in Phase 1 and 2 clinical trials | Deusch K et al. | Diabetes, obesity & metabolism | 2025 | Randomized Controlled Trial |
| Combined agonism of nutrient receptors GPR40 and GPR119 with K-757 and K-833 results in weight loss and blood pressure reductions in obese subjects without type 2 diabetes mellitus | Crutchlow M et al. | Diabetes, obesity & metabolism | 2025 | Randomized Controlled Trial |
| Regulation of proglucagon derived peptides by carbohydrate and protein ingestion in young healthy males-A randomized, double-blind, cross-over trial | Skarmaliorakis I et al. | Clinical nutrition (Edinburgh, Scotland) | 2025 | Randomized Controlled Trial |
| Response to lowering plasma glucose is characterised by decreased oxyntomodulin: Results from a randomised controlled trial | Liu Y et al. | Diabetes & metabolic syndrome | 2024 | Randomized Controlled Trial |
| Tripeptide gut hormone infusion does not alter food preferences or sweet taste function in volunteers with obesity and prediabetes/diabetes but promotes restraint eating: A secondary analysis of a randomized single-blind placebo-controlled study | Behary P et al. | Diabetes, obesity & metabolism | 2023 | Randomized Controlled Trial |
| Circulating levels of five proglucagon-derived peptides in response to intravenous or oral glucose or lipids and to a mixed-meal in subjects with normal weight, overweight, and obesity | Perakakis N et al. | Clinical nutrition (Edinburgh, Scotland) | 2022 | Clinical Trial |
| Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial | Perakakis N et al. | Metabolism: clinical and experimental | 2022 | Randomized Controlled Trial |
| The Metabolomic Effects of Tripeptide Gut Hormone Infusion Compared to Roux-en-Y Gastric Bypass and Caloric Restriction | Jones B et al. | The Journal of clinical endocrinology and metabolism | 2022 | Randomized Controlled Trial |
| Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose-ranging study | Di Prospero NA et al. | Clinical obesity | 2021 | Randomized Controlled Trial |
| Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover study | McGlone ER et al. | American journal of physiology. Endocrinology and metabolism | 2021 | Randomized Controlled Trial |
| Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trial | Kim SH et al. | Diabetes, obesity & metabolism | 2021 | Randomized Controlled Trial |
| Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS | Shah A et al. | The Journal of clinical endocrinology and metabolism | 2021 | Randomized Controlled Trial |
| The Mediterranean diet increases glucagon-like peptide 1 and oxyntomodulin compared with a vegetarian diet in patients with type 2 diabetes: A randomized controlled cross-over trial | Di Mauro A et al. | Diabetes/metabolism research and reviews | 2021 | Randomized Controlled Trial |
| Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: Evidence from two independent trials | Perakakis N et al. | Metabolism: clinical and experimental | 2019 | Clinical Trial |
| Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study | Behary P et al. | Diabetes care | 2019 | Randomized Controlled Trial |
| Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes | Shankar SS et al. | Diabetes | 2018 | Randomized Controlled Trial |
| The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers | Tan T et al. | The Journal of clinical endocrinology and metabolism | 2017 | Randomized Controlled Trial |
| Oxyntomodulin analog and exendin-4 derivative lower plasma glucose in cattle | ThanThan S et al. | Domestic animal endocrinology | 2017 | Randomized Controlled Trial |
| Postprandial effects of consuming a staggered meal on gut peptide and glycemic responses in obese women and men | Griffith L et al. | Obesity research & clinical practice | 2016 | Randomized Controlled Trial |
| Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure | Bagger JI et al. | The Journal of clinical endocrinology and metabolism | 2015 | Randomized Controlled Trial |
| Increased gut hormones and insulin sensitivity index following a 3-d intervention with a barley kernel-based product: a randomised cross-over study in healthy middle-aged subjects | Nilsson AC et al. | The British journal of nutrition | 2015 | Randomized Controlled Trial |
| Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle | ThanThan S et al. | Domestic animal endocrinology | 2013 | Clinical Trial |
| B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men | Vila G et al. | Diabetes | 2012 | Randomized Controlled Trial |
| Effect of abomasal glucose infusion on plasma concentrations of gut peptides in periparturient dairy cows | Larsen M et al. | Journal of dairy science | 2010 | Randomized Controlled Trial |
| Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes | Laferrère B et al. | The Journal of clinical endocrinology and metabolism | 2010 | Clinical Trial |
| PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans | Field BC et al. | Diabetes | 2010 | Randomized Controlled Trial |
| Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial | Wynne K et al. | International journal of obesity (2005) | 2006 | Randomized Controlled Trial |
| Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial | Wynne K et al. | Diabetes | 2005 | Randomized Controlled Trial |
| Oxyntomodulin suppresses appetite and reduces food intake in humans | Cohen MA et al. | The Journal of clinical endocrinology and metabolism | 2003 | Randomized Controlled Trial |